RJFSA
KPRX icon

Raymond James Financial Services Advisors’s Kiora Pharmaceuticals KPRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3
Closed -$5K – 2702
2018
Q3 		$5K Hold
3
– – ﹤0.01% 2798
2018
Q2 		$8K Buy
+3
New +$8.46K ﹤0.01% 2755

Other funds holding KPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James Financial Services Advisors's KPRX Position: Q4 2018 in Review

Raymond James Financial Services Advisors sold out of Kiora Pharmaceuticals (KPRX) in Q4 2018, closing a stake of 3 shares — an estimated $5K sold.

Raymond James Financial Services Advisors first reported a position in KPRX in Q2 2018 and held it in 2 quarters. The position peaked at $8K in Q2 2018. 13 funds tracked by Wall St. Rank hold KPRX as of Q4 2018.

  • Raymond James Financial Services Advisors reported no remaining Kiora Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 3 Kiora Pharmaceuticals shares in Q4 2018, an estimated $5K.
  • Raymond James Financial Services Advisors first reported a position in Kiora Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Kiora Pharmaceuticals position peaked at $8K in Q2 2018.
  • 13 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.